Ionis Pharmaceuticals, Inc. (IONS)

36.94 -0.17 (-0.46%) As of 09:32AM EDT. Market open.

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200
https://www.ionispharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 660

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Brett P. Monia Ph.D.	Founder, CEO & Director	1.32M	N/A	1961
Ms. Elizabeth L. Hougen	Exec. VP of Fin. & CFO	869.38k	N/A	1962
Ms. Onaiza Cadoret-Manier	Exec. VP and Chief Product Strategy & Operations Officer	755.52k	N/A	1965
Mr. Patrick R. O'Neil Esq.	Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.	815.69k	N/A	1974
Dr. Stanley T. Crooke	Scientific Advisor	1.64M	N/A	1945
Ms. B. Lynne Parshall Esq., J.D.	Sr. Strategic Advisor & Director	701.77k	N/A	1954
Dr. Eric E. Swayze Ph.D.	Exec. VP of Research	739.3k	N/A	1966
Mr. Joel Edwards	VP of Corp. Operations	N/A	N/A	1961
Mr. Darren Gonzales	Chief Accounting Officer & Sr. VP	N/A	N/A	N/A
Dr. C. Frank Bennett	Exec. VP & Chief Scientific Officer	N/A	N/A	1957

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.